Screener
CalAmp CAMP Q2 2026 earnings
Reported August 13, 2026 · After market close
Revenue$1.8MBeat by $159.0K
EPS-$0.58Miss by $0.37
Revenue estimate$1.6M
EPS estimate-$0.21
“Having secured regulatory clearance in both Australia and Argentina, we are now focused on initiating our first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1 and are continuing to activate our planned clinical trial in additional jurisdictions. There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives.”
Next report
Date not yet announcedValuation & ratios
Segments
By segment
Versus estimates
Revenue
Diluted EPS
FAQ
- When did CalAmp report Q2 2026 earnings?
- CalAmp (CAMP) reported Q2 2026 earnings on August 13, 2026 after market close.
- What were CalAmp's Q2 2026 revenue and EPS?
- CalAmp reported revenue of $1.8M and eps of $-0.58 for Q2 2026.
- Did CalAmp beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $1.6M by $159.0K. EPS missed the consensus estimate of $-0.21 by $0.37.
- How did CalAmp's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 18.8% from $1.5M a year earlier and eps grew 6.5% from $-0.62.
- Where can I find CalAmp's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-056758) and the 10-Q periodic report (0001628280-26-056760) directly on SEC EDGAR. The filing index links above go to sec.gov.
